Bank of New York Mellon’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-736,241
| Closed | -$3.02M | – | 4770 |
|
|
2022
Q1 | $3.02M | Buy |
736,241
+17,151
| +2% | +$62.2K | ﹤0.01% | 2699 |
|
|
2021
Q4 | $2.57M | Buy |
719,090
+123,262
| +21% | +$431K | ﹤0.01% | 2841 |
|
|
2021
Q3 | $2.17M | Buy |
595,828
+24,787
| +4% | +$100K | ﹤0.01% | 2937 |
|
|
2021
Q2 | $2.49M | Sell |
571,041
-105,664
| -16% | -$430K | ﹤0.01% | 2856 |
|
|
2021
Q1 | $2.78M | Sell |
676,705
-14,628
| -2% | -$63.4K | ﹤0.01% | 2736 |
|
|
2020
Q4 | $2.76M | Buy |
691,333
+44,409
| +7% | +$144K | ﹤0.01% | 2659 |
|
|
2020
Q3 | $1.75M | Sell |
646,924
-1,621
| -0.2% | -$4.49K | ﹤0.01% | 2751 |
|
|
2020
Q2 | $1.78M | Buy |
648,545
+19,176
| +3% | +$53.5K | ﹤0.01% | 2750 |
|
|
2020
Q1 | $1.49M | Sell |
629,369
-176,850
| -22% | -$602K | ﹤0.01% | 2708 |
|
|
2019
Q4 | $3.79M | Buy |
806,219
+178,354
| +28% | +$730K | ﹤0.01% | 2474 |
|
|
2019
Q3 | $2.1M | Sell |
627,865
-10,738
| -2% | -$35.4K | ﹤0.01% | 2734 |
|
|
2019
Q2 | $2.1M | Buy |
638,603
+18,111
| +3% | +$52.4K | ﹤0.01% | 2771 |
|
|
2019
Q1 | $1.88M | Sell |
620,492
-16,419
| -3% | -$53.2K | ﹤0.01% | 2803 |
|
|
2018
Q4 | $1.73M | Buy |
636,911
+138,756
| +28% | +$457K | ﹤0.01% | 2799 |
|
|
2018
Q3 | $1.67M | Sell |
498,155
-17,927
| -3% | -$55.4K | ﹤0.01% | 2954 |
|
|
2018
Q2 | $1.33M | Sell |
516,082
-47,049
| -8% | -$117K | ﹤0.01% | 3092 |
|
|
2018
Q1 | $1.24M | Buy |
563,131
+17,345
| +3% | +$39K | ﹤0.01% | 3099 |
|
|
2017
Q4 | $1.09M | Buy |
545,786
+9,661
| +2% | +$21K | ﹤0.01% | 3201 |
|
|
2017
Q3 | $1.74M | Buy |
536,125
+10,619
| +2% | +$32.8K | ﹤0.01% | 2919 |
|
|
2017
Q2 | $1.69M | Buy |
525,506
+357,991
| +214% | +$1.01M | ﹤0.01% | 2947 |
|
|
2017
Q1 | $476K | Buy |
167,515
+28,029
| +20% | +$67.4K | ﹤0.01% | 3573 |
|
|
2016
Q4 | $325K | Sell |
139,486
-15,412
| -10% | -$29.3K | ﹤0.01% | 3758 |
|
|
2016
Q3 | $260K | Sell |
154,898
-88,159
| -36% | -$108K | ﹤0.01% | 3816 |
|
|
2016
Q2 | $256K | Sell |
243,057
-334,216
| -58% | -$323K | ﹤0.01% | 3807 |
|
|
2016
Q1 | $502K | Buy |
577,273
+3,220
| +0.6% | +$3.12K | ﹤0.01% | 3434 |
|
|
2015
Q4 | $694K | Sell |
574,053
-241,026
| -30% | -$335K | ﹤0.01% | 3378 |
|
|
2015
Q3 | $1.39M | Sell |
815,079
-16,194
| -2% | -$31.7K | ﹤0.01% | 2980 |
|
|
2015
Q2 | $1.73M | Buy |
831,273
+130,077
| +19% | +$315K | ﹤0.01% | 3014 |
|
|
2015
Q1 | $1.9M | Buy |
701,196
+36,626
| +6% | +$92.9K | ﹤0.01% | 2901 |
|
|
2014
Q4 | $1.71M | Sell |
664,570
-690
| -0.1% | -$1.55K | ﹤0.01% | 2972 |
|
|
2014
Q3 | $1.22M | Sell |
665,260
-284,776
| -30% | -$621K | ﹤0.01% | 3177 |
|
|
2014
Q2 | $2.54M | Buy |
950,036
+27,294
| +3% | +$82.1K | ﹤0.01% | 2754 |
|
|
2014
Q1 | $3.23M | Buy |
922,742
+98,979
| +12% | +$439K | ﹤0.01% | 2572 |
|
|
2013
Q4 | $3.68M | Buy |
823,763
+90,110
| +12% | +$367K | ﹤0.01% | 2485 |
|
|
2013
Q3 | $2.98M | Buy |
733,653
+92,863
| +14% | +$406K | ﹤0.01% | 2571 |
|
|
2013
Q2 | $2.67M | Buy |
+640,790
| New | +$2.48M | ﹤0.01% | 2600 |
|
Other funds holding ATRS
Bank of New York Mellon's ATRS Position: Q2 2022 in Review
Bank of New York Mellon sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 736,241 shares — an estimated $3.02M sold.
Bank of New York Mellon first reported a position in ATRS in Q2 2013 and held it in 36 quarters. The position peaked at $3.79M in Q4 2019. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- Bank of New York Mellon reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- Bank of New York Mellon sold 736,241 Antares Pharma, Inc. shares in Q2 2022, an estimated $3.02M.
- Bank of New York Mellon first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 36 quarters.
- Bank of New York Mellon's Antares Pharma, Inc. position peaked at $3.79M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on Bank of New York Mellon's 13F filing for Q2 2022, filed 15 Aug 2022.